Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab with Chemotherapy in Locally Advanced Cervical Cancer
NCT07055399Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Started Aug 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07055399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055399.